1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
elexxion AG

elexxion AG

E8X.DE
elexxion AGDE flagDeutsche Börse
0.14
EUR
+0.00
- -
1.47MMarket Cap
elexxion AG
E8X.DE
(Deutsche Börse)

Recent

price

0.14

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
FRC
- -
- -
- -
0.26
0.41
0.25
0.25
0.19
0.2
0.17
0.15
0.07
- -
0.07
- -
- -
Revenue per Share
- -
- -
- -
-0.23
-0.2
-0.2
-0.14
-0.08
-0.07
0.08
-0.13
-0.1
- -
-0.07
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.69
-0.73
-0.6
-0.59
-0.67
-0.75
-0.66
-0.79
-0.89
- -
-0.9
- -
- -
Book Value per Share
- -
- -
- -
0.12
0.01
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
6
7
8
9
9
9
9
9
9
- -
10
- -
- -
Basic Weighted Avg Shares
3
3
2
2
3
2
2
2
2
1
1
1
1
1
1
- -
Sales/Revenue/Turnover
-55.9
-64.38
-64.84
-112.41
-47.8
-77.18
-50.63
-36.42
-29
60.24
-80.95
-125.4
-144.65
-79.63
-24.21
-195.12
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-3
-2
-1
-1
-2
-1
-1
-1
1
-1
-1
-1
-1
- -
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.07
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-62.67
-103.34
-90.91
-88.36
-48.32
-79.25
-54.14
-43.12
-36.66
50.99
-87.14
-139.1
-158.92
-93.8
-34.84
-221.47
Profit Margin (%)
1
- -
-2
1
1
- -
- -
1
1
1
1
1
1
1
1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
2
2
3
3
4
LT Debt
3
2
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
110.04
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-16.17
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-45.8%
17.23%
174.28%
Sales/Revenue/Turnover
-9.12%
-11.19%
-56.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
1
2021
- -
- -
- -
- -
1
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-0.07
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
TransMedics Group, Inc. (TMDX)
Bonesupport Holding AB (publ) (BOEUF)
Edan Instruments, Inc. (300206.SZ)
PHC Holdings Corporation (6523.T)
Envoy Medical, Inc. (COCH)
Evome Medical Technologies Inc. (LNDZF)
Business
elexxion AG develops, produces and sells advanced dental laser systems for soft and hard tissue applications primarily in Germany and internationally. The company offers high-performance diode lasers including the claros series up to 50W with variable pulsing up to 20,000 Hz for surgery, periodontology and periimplantitis treatment; the pico and nano series for decontamination, soft tissue procedures and minimally invasive therapies; the pico lite for soft laser therapy and activation of photothermal treatments; SNORE3 therapy for non-invasive anti-snoring applications; Odobleach for whitening; and perio green, an innovative photothermal therapy product for periodontology and periimplantitis. Founded in 2002 and headquartered at Otto-Hahn-Straße 7 in Singen, Germany, elexxion AG operates as a subsidiary of Tian Ying Medical Instrument Co., Ltd., which increased its ownership to 85% in 2017 following an initial 55% acquisition in 2016. Recent developments include the introduction of a new generation of dental lasers featuring enhanced power capabilities and the release of its 2023 annual financial statements in October 2025, alongside historical capital increases such as the EUR 899,000 raise in 2019 and various share issuances in 2022-2023. The company maintains in-house research, development and production facilities, positioning it as a leader in high-peak-power pulsed laser technology for low-pain, syringe-free dental procedures targeting dentists, oral surgeons and specialized clinics.